GURPREET S SANDHU
Medical Practice at 1 St, Rochester, MN

8544474, Oct 1, 2013

Dec 19, 2008

12/809197

Gurpreet S. Sandhu - Rochester MN, US
Robert D. Simari - Rochester MN, US
Nicole P. Sandhu - Rochester MN, US

Mayo Foundation for Medical Education and Research - Rochester MN

A61B 19/00

128899, 128897, 600 13

Systems and methods that provide magnetically-enhanced delivery of therapeutic agents to selected tissue are disclosed. The systems and methods involve the use of carrier devices and release devices and two different magnetic fields to move magnetic particles into selected tissue. Movement of the magnetic particles (and any associated therapeutic agent) into the tissue may be assisted by both magnetic attractive forces as well as magnetic repulsive forces.

8465453, Jun 18, 2013

Jun 5, 2006

11/446861

Gurpreet S. Sandhu - Rochester MN, US
Robert D. Simari - Rochester MN, US
Nicole P. Sandhu - Rochester MN, US
Rajiv Gulati - Rochester MN, US

Mayo Foundation for Medical Education and Research - Rochester MN

A61M 29/00, A61M 25/00, A61M 25/10

604 9601, 60410101, 60410103, 60410201, 60410202, 60410203, 623 111, 623 123

Medical devices with surfaces on which viable biologic cells are magnetically attracted and retained are disclosed along with methods of magnetic coating. The medical devices can be located in a carrier liquid containing high concentrations of magnetic cells before or after implantation. The carrier liquid with magnetic cells may be contact with the medical device in vitro or in vivo. In either case, the carrier liquid may have a concentration of magnetic cells that is high enough to facilitate coating of the medical device within an acceptable period of time, e. g. , several hours or less. Magnetization of medical devices before, during, and/or after implantation and apparatus for performing the same are disclosed. Degaussing of magnetic medical devices is also disclosed.

5958693, Sep 28, 1999

Sep 22, 1997

8/934877

Gurpreet S. Sandhu - Rochester MN
Bruce C. Kline - Rochester MN

Bayer Corporation - E. Walpole MA

C12Q 168

435 6

Nucleic acid probes and primers are described for detecting fungi that cause disease in humans and animals, as well as spoilage of food and beverages. These probes can detect rRNA, rDNA or polymerase chain reaction products from a majority of fungi in clinical, environmental or food samples. Nucleic acid hybridization assay probes specific for Acremonium sp. , Aspergillus clavatus, Aspergillus flavus, Aspergillus fumigatus, Aspergillus glaucus, Aspergillus nidulans, Aspergillus niger, Aspergillus ochraceus, Aspergillus terreus, Aspergillus unguis, Aspergillus ustus, Beauveria sp. , Bipolaris sp. , Blastoschizomyces sp. , Blastomyces dermatitidis, Candida albicans, Candida glabrata, Candida guilliermondii, Candida kefyr, Candida krusei, Candida lusitaniae, Candida parapsilosis, Candida tropicalis, Chrysosporium sp. , Cladosporium sp. , Coccidioides immitis, Cryptococcus neoformans var gattii serotype B, Cryptococcus neoformans serotype A, Cryptococcus laurentii, Cryptococcus terreus, Curvularia sp.

5731150, Mar 24, 1998

Nov 1, 1995

8/551645

Gurpreet S. Sandhu - Rochester MN
Bruce C. Kline - Rochester MN
Leslie Stockman - Rochester MN
Glenn D. Roberts - Rochester MN
Marcia E. Lewis - Cohasset MA

Chiron Diagnostic Corporation - East Walpole MA

C12Q 168, C12P 1934, C07H 2104, C07H 2100

435 6

The detection of the IS6110 insertion element in a clinical specimen is a rapid way of diagnosing infection by Mycobacterium tuberculosis. A reliable diagnostic test for tuberculosis based on the IS6110 DNA is described in this disclosure. A "Universal" specimen preparation protocol that eliminates live organisms and purifies nucleic acids from all types of clinical specimens is described. Two nucleic acid primers designed to amplify IS6110 DNA with high specificity in a polymerase chain reaction are also described. The amplified IS6110 DNA is identified by a restriction endonuclease and electrophoresis based assay. The identification process also renders the DNA unamplifiable in a subsequent PCR, thereby reducing the possibility of contaminating other specimens. Time, labor and cost is minimized, while user safety and test reliability are maximized. The complete DNA extraction, amplification and analysis is accomplished with ease within an 8 hour period, with a sensitivity of 92% and a specificity approaching 100%.

2010003, Feb 4, 2010

May 22, 2007

12/302142

Gurpreet S. Sandhu - Rochester MN, US
Charanjit S. Rihal - Rochester MN, US

Mayo Foundation for Medical Education and Research - Rochester MN

A61M 29/00, A61M 25/00

606194, 604264

Devices and methods for crossing total chronic occlusions in body lumens (e.g., blood vessels, etc.). The devices and methods may involve guidewire assisted delivery of a device designed to both traverse a chronic total occlusion (CTO) and create a passageway through the CTO for a treatment device (e.g., an angioplasty balloon, stent, etc.). Some devices of the present invention may include an expandable sleeve constructed of material that expands in response to temperature changes. In other devices, an expandable sleeve may be provided in which two or more interlocking cylindrical sections can be arranged such that the cylindrical sections have a first, smaller diameter at which the expandable sleeve can be inserted through a CTO. The expandable sleeve also has a second, larger diameter that can be achieved by moving the two or more interlocking cylindrical sections relative to each other such that the expandable sleeve moves from the first diameter to the second diameter when the expandable sleeve is located across the CTO. In other aspects, a guide catheter may include a friction-enhanced outer surface to assist in maintaining the guide catheter in a selected location during use. The friction-enhanced property may be provided using, e.g., materials with an increased coefficient of friction, adding features to the surface of an otherwise smooth guide catheter, etc.

2011025, Oct 20, 2011

Nov 13, 2009

13/129298

David R. Holmes - Rochester MN, US
Gurpreet S. Sandhu - Rochester MN, US
Robert D. Simari - Rochester MN, US
Nicole P. Sandhu - Rochester MN, US
Jonathan Harburn - Tyne & Wear, GB

A61M 37/00, A61P 35/00, A61K 38/02

600 9, 514 11

This document relates to molecularly imprinted polymers for use in mammals. For example, methods and materials for capturing a molecule in the body of a mammal using a molecularly imprinted polymer are provided. In some cases methods for delivering a molecule using a molecularly imprinted polymer into the body of a mammal are provided. The methods provided can be used to target any molecule in the body of a mammal.

2011011, May 19, 2011

Jan 25, 2011

13/013559

Gurpreet S. SANDHU - Rochester MN, US
Robert D. Simari - Rochester MN, US
Nicole P. Sandhu - Rochester MN, US
Rajiv Gulati - Rochester MN, US

Mayo Foundation for Medical Education and Research - Rochester MN

A61F 2/82

623 115

Medical devices with surfaces on which viable biologic cells are magnetically attracted and retained are disclosed along with methods of magnetic coating. The medical devices can be located in a carrier liquid containing high concentrations of magnetic cells before or after implantation. The carrier liquid with magnetic cells may be contact with the medical device in vitro or in vivo. In either case, the carrier liquid may have a concentration of magnetic cells that is high enough to facilitate coating of the medical device within an acceptable period of time, e.g., several hours or less. Magnetization of medical devices before, during, and/or after implantation and apparatus for performing the same are disclosed. Degaussing of magnetic medical devices is also disclosed.

8544309, Oct 1, 2013

Feb 26, 2008

12/037352

Gurpreet S. Sandhu - Rochester MN, US

Mayo Foundation for Medical Education and Research - Rochester MN

B21D 41/02, B21D 39/08

72317, 7237006, 723701

Apparatus, kits and methods for flaring an end of a stent that can then be placed within the ostium of a vessel are disclosed. Areas in which ostial stents with flared ends could be used may include, e. g. , the left main artery, renal arteries, sub-clavian artery, right coronary artery, circumflex artery, et al.

2010029, Nov 18, 2010

Jan 5, 2009

12/812530

Gurpreet S. Sandhu - Rochester MN, US
Charanjit S. Rihal - Rochester MN, US
Rajiv Gulati - Rochester MN, US
John F. Bresnahan - Rochester MN, US

A61F 2/82

623 123

Materials and methods for placement of catheters, stents, and other therapeutic or diagnostic devices in blood vessels.

2010012, May 13, 2010

Oct 10, 2007

12/445062

Gurpreet S. Sandhu - Rochester MN, US
Nicole P. Sandhu - Rochester MN, US
Robert D. Simari - Rochester MN, US

A61B 6/10, A61M 25/00, A61M 25/10

600435, 604523, 604 9601, 604508

This document provides methods and materials that can be used to reduce or prevent contrast agent-induced toxicity. For example, devices for capturing contrast agents from blood are provided.